Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC

被引：3

作者：

Kurata, Takayasu ^{[1
]}

Nakagawa, Kazuhiko ^{[2
]}

Satouchi, Miyako ^{[3
]}

Seto, Takashi ^{[4
]}

Sawada, Takeshi ^{[5
]}

Han, Shi Rong ^{[5
]}

Noguchi, Kazuo ^{[5
]}

Shimamoto, Takashi ^{[5
]}

Nogami, Naoyuki ^{[6
]}

机构：

[1] Kansai Med Univ Hosp, Osaka, Japan

[2] Kindai Univ, Fac Med, Dept Med Oncol, Sayama, Osaka, Japan

[3] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan

[4] Natl Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan

[5] MSD KK, Tokyo, Japan

[6] Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol, Matsuyama, Ehime, Japan

来源：

关键词：

D O I：

10.1093/annonc/mdz338.105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO3 - 9 -

引用

页数：1